Advisory Board
Introducing ACI’s Biosimilars & Innovator Biologics Advisory Board
American Conference Institute's Biosimilars & Innovator Biologics Advisory Board was created as a part of ACI’s ongoing effort to provide industry leading content and a world-renowned speaker faculty. The board is composed of a selection of all-in-house advisers, including senior IP/Patent counsel from the leading pharmaceutical companies in the country and in some cases the world. This ‘inner circle’ counsels ACI on the impact of litigation trends and emerging topics.
Ali I. Ahmed
Senior Vice President, Biosimilars
Fresenius Kabi USA
Neal Dahiya
SVP, Head of Litigation
Moderna
Henry Gu
Vice President, Head of IP
Morphic Therapeutic
Scott Kamholz
Vice President of Intellectual Property
Tessera Therapeutics
Brian McCormick
Vice President - Chief Regulatory Counsel, Head of Global Regulatory Policy
Teva Pharmaceuticals
Julia Pike
Global Head of IP
Sandoz
Juliana “Julie” Reed
Vice President, Global Corporate Affairs Lead Immunology, Inflammation (I&I) and Biosimilars
Pfizer
Chuck Sholtz
Director and Associate General Counsel, Biosimilars
Manufacturing & Litigation Readiness Lead
Genentech
